scholarly journals Timing of Development of Symptomatic Brain Metastases from Non-Small Cell Lung Cancer: Impact on Symptoms, Treatment, and Survival in the Era of Molecular Treatments

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3618
Author(s):  
Stephanie T. Jünger ◽  
Petra Schödel ◽  
Daniel Ruess ◽  
Maximilian Ruge ◽  
Julia-Sarita Brand ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Status ◽  
Small Cell ◽  
Karnofsky Performance Score ◽  
Small Cell Lung ◽  
Early Presentation

Objective: We attempted to analyze whether early presentation with brain metastases (BM) represents a poor prognostic factor in patients with non-small cell lung cancer (NSCLC), which should guide the treatment team towards less intensified therapy. Patients and methods: In a retrospective bi-centric analysis, we identified patients receiving surgical treatment for NSCLC BM. We collected demographic-, tumor-, and treatment-related parameters and analyzed their influence on further survival. Results: We included 377 patients. Development of BM was precocious in 99 (26.3%), synchronous in 152 (40.3%), and metachronous in 126 (33.4%) patients. The groups were comparable in terms of age (p = 0.76) and number of metastases (p = 0.11), and histology (p = 0.1); however, mutational status significantly differed (p = 0.002). The precocious group showed the worst clinical status as assessed by Karnofsky performance score (KPS) upon presentation (p < 0.0001). Resection followed by postoperative radiotherapy was the predominant treatment modality for precocious BM, while in syn- and metachronous BM surgical and radio-surgical treatment was balanced. Overall survival (OS) did not differ between the groups (p = 0.76). A good postoperative clinical status (KPS ≥ 70) and the application of any kind of adjuvant systemic therapy were independent predictive factors for OS. Conclusion: Early BM presentation was not associated with worse OS in NSCLC BM patients.

scholarly journals Surgical Treatment of Non-Small Cell Lung Cancer with Isolated Synchronous Brain Metastases

2006 ◽  
Vol 21 (2) ◽  
pp. 236 ◽  
Author(s):  
Hoseok I ◽  
Jung Il Lee ◽  
Do Hyun Nam ◽  
Yong Chan Ahn ◽  
Young Mog Shim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important?

Lung Cancer ◽  
2014 ◽  
Vol 86 (2) ◽  
pp. 185-189 ◽  
Author(s):  
Emma L. O’Dowd ◽  
Maruti Kumaran ◽  
Sadia Anwar ◽  
Begoña Palomo ◽  
David R. Baldwin
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Brain Imaging ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Surgical treatment strategy for small-sized, non-small cell lung cancer: A proposed algorithm for limited resection

2010 ◽  
Vol 24 (7) ◽  
pp. 1004-1010 ◽  
Author(s):  
Masayoshi Inoue ◽  
Masato Minami ◽  
Noriyoshi Sawabata ◽  
Yoshihisa Kadota ◽  
Yasushi Shintani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Strategy ◽  
Small Cell ◽  
Limited Resection ◽  
Small Cell Lung

scholarly journals 38P Brain metastases in non-small cell lung cancer in era of molecularly driven therapy

2021 ◽  
Vol 16 (4) ◽  
pp. S714-S715
Author(s):  
S. Rakshit ◽  
R. Bansal ◽  
A. Desai ◽  
K. Leventakos
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1562
Author(s):  
Konstantinos Rounis ◽  
Marcus Skribek ◽  
Dimitrios Makrakis ◽  
Luigi De Petris ◽  
Sofia Agelaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Disease Progression ◽  
Cell Lung Cancer ◽  
Response Assessment ◽  
Small Cell ◽  
University Hospital ◽  
Response Analysis ◽  
Small Cell Lung

There is a paucity of biomarkers for the prediction of intracranial (IC) outcome in immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM). We identified 280 NSCLC pts treated with ICIs at Karolinska University Hospital, Sweden, and University Hospital of Heraklion, Greece. The inclusion criteria for response assessment were brain metastases (BM) prior to ICI administration, radiological evaluation with CT or MRI for IC response assessment, PD-1/PD-L1 inhibitors as monotherapy, and no local central nervous system (CNS) treatment modalities for ≥3 months before ICI initiation. In the IC response analysis, 33 pts were included. Non-primary (BM not present at diagnosis) BM, odds ratio (OR): 13.33 (95% CI: 1.424–124.880, p = 0.023); no previous brain radiation therapy (RT), OR: 5.49 (95% CI: 1.210–25.000, p = 0.027); and age ≥70 years, OR: 6.19 (95% CI: 1.27–30.170, p = 0.024) were associated with increased probability of IC disease progression. Two prognostic groups (immunotherapy (I-O) CNS score) were created based on the abovementioned parameters. The I-O CNS poor prognostic group B exhibited a higher probability for IC disease progression, OR: 27.50 (95% CI: 2.88–262.34, p = 0.004). Age, CNS radiotherapy before the start of ICI treatment, and primary brain metastatic disease can potentially affect the IC outcome of NSCLC pts with BM.

Sign in / Sign up

Export Citation Format

Share Document